Cryo-Cell International, Inc. Reports Second Quarter 20...(decrease or slowdown in thenumber of peo...)

Date:7/10/2008

decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company.

Contact:

Mona J. Walsh (Investors)

Edelman

212-704-4598

mona.walsh@edelman.com

Kristin O'Neill (Media Inquiries)

Edelman

312-233-1295

kristin.oneill@edelman.com

'/>"/>

SOURCE Cryo-Cell International, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
4. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
5. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
6. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
7. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
8. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
9. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
10. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
11. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK